Related Experiment Videos
Sentinel lymph node biopsy in breast cancer
1Department of Surgery, 251 Hellenic Air Forces General Hospital, Athens, Greece.
The American Surgeon
|August 5, 2000
Summary
Sentinel lymph node (SLN) biopsy offers a less invasive method for assessing breast cancer spread. This technique accurately stages axillary lymph nodes, guiding treatment decisions with minimal patient morbidity.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Axillary lymph node status is a critical prognostic factor in breast cancer.
- Sentinel lymph node (SLN) biopsy is a less invasive alternative to axillary dissection for early-stage, node-negative breast cancer.
Purpose of the Study:
- To evaluate the efficacy of SLN biopsy in assessing axillary nodal status in early breast cancer patients.
- To highlight the multidisciplinary approach required for successful SLN biopsy.
Main Methods:
- SLN biopsy involves a coordinated effort between surgeons, nuclear radiologists, and pathologists.
- Complementary techniques, including blue dye and lymphoscintigraphy, maximize success rates.
- Focused histopathologic examination of SLN(s) using serial sectioning and immunohistochemistry enhances staging accuracy.
Main Results:
- SLN biopsy provides adequate assessment of axillary nodal status with minimal morbidity.
- Combined techniques (blue dye and lymphoscintigraphy) improve the success rate of SLN identification.
- Detailed examination of SLN(s) allows for improved cancer staging.
Conclusions:
- SLN biopsy is an effective method for staging early breast cancer, guiding further treatment like surgery and chemotherapy.
- The procedure should be performed by experienced surgeons to achieve a low failure rate (<2%).
- Long-term outcome data are pending, and the method is currently considered investigational.